SNDX Stock Analysis: Syndax Pharmaceuticals | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.933m USD | 12M Return: 166.2% | Charts, Fundamentals & Technical Analysis

Menin Inhibitors, CSF-1R Antibodies, HDAC Inhibitors, Oncology Therapies
Total Rating 34
Safety 26
Buy Signal 0.04
Biotechnology
Industry Rotation: +30.9
Market Cap: 1.93B
Avg Turnover: 39.4M
Risk 3d forecast
Volatility53.2%
VaR 5th Pctl8.65%
VaR vs Median-1.32%
Reward TTM
Sharpe Ratio1.93
Rel. Str. IBD86.1
Rel. Str. Peer Group49.3
Character TTM
Beta0.748
Beta Downside1.027
Hurst Exponent0.546
Drawdowns 3y
Max DD64.81%
CAGR/Max DD0.07
CAGR/Mean DD0.18
EPS (Earnings per Share) EPS (Earnings per Share) of SNDX over the last years for every Quarter: "2021-06": -0.44, "2021-09": -0.4, "2021-12": 1.81, "2022-03": -0.63, "2022-06": -0.62, "2022-09": -0.58, "2022-12": -0.62, "2023-03": -0.59, "2023-06": -0.64, "2023-09": -0.73, "2023-12": -1, "2024-03": -0.85, "2024-06": -0.8, "2024-09": -0.98, "2024-12": -1.1, "2025-03": -0.98, "2025-06": -0.83, "2025-09": -0.7, "2025-12": -0.78, "2026-03": -0.48,
Last SUE: 0.30
Qual. Beats: 0
Revenue Revenue of SNDX over the last years for every Quarter: 2021-06: 0.379, 2021-09: 12.375, 2021-12: 126.576, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.536, 2024-03: 0, 2024-06: 3.5, 2024-09: 12.5, 2024-12: 7.68, 2025-03: 20.042, 2025-06: 37.958, 2025-09: 45.871, 2025-12: 68.481, 2026-03: 64.864,
Last SUE: -0.17
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Beneish M-Score Likely Earnings Manipulation
Altman Z'' In Financial Distress Zone
Extended 3d

Tailwinds

No distinct edge detected

Seasonality 10.3 years of data

Jan +1.8% 6
Feb +5.6% 24
Mar +1.9% 14
Apr -7.5% 27
May -6.9% 31
Jun -0.3% 0
Jul +0.0% 11
Aug +11.7% 10
Sep -1.9% 22
Oct -2.8% 35
Nov +5.7% 20
Dec +0.0% 11

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: SNDX Syndax Pharmaceuticals

Syndax Pharmaceuticals (NASDAQ: SNDX) is a New York-based commercial-stage biopharmaceutical company, incorporated in 2005, that develops oncology therapies. It markets two lead products: Revuforj (revumenib), a menin inhibitor for relapsed or refractory acute leukemia, and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor (CSF-1R) blocking antibody for chronic graft-versus-host disease. The pipeline expands revumenib into additional acute myeloid leukemia (AML) indications and metastatic colorectal cancer, explores axatilimab in idiopathic pulmonary fibrosis, and includes Entinostat, a Class I HDAC inhibitor that is licensed to Eddingpharm International for development and commercialization in certain markets.

Operating in the biotechnology sub-industry of the health care sector, Syndax uses a targeted-therapy model, building a portfolio around small-molecule inhibitors and monoclonal antibodies designed against specific oncogenic drivers and immune-modulating pathways. As a commercial-stage small-cap biotech, it supplements its in-house development with out-licensing partnerships to extend geographic reach and share clinical and commercial risk.

Headlines to Watch Out For
  • Revuforj revenue ramp accelerates in relapsed acute leukemia
  • Niktimvo launch uptake scales in chronic graft-versus-host disease
  • Revumenib label expansion into mNPM1 AML and combinations
Piotroski VR-10 (Strict) 0.5
Net Income: -243.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.41 > 0.02 and ΔFCF/TA 3.61 > 1.0
NWC/Revenue: 177.3% < 20% (prev 1.04k%; Δ -861.6% < -1%)
CFO/TA -0.59 > 3% & CFO -278.2m > Net Income -243.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.47 > 1.5 & < 3
Outstanding Shares: last quarter (86.6m) vs 12m ago 1.17% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 39.01% > 50% (prev 6.82%; Δ 32.19% > 0%)
Interest Coverage Ratio: -2.01 > 6 (EBIT TTM -162.6m / Interest Expense TTM 80.7m)
Altman Z'' -7.20
A: 0.81 (Total Current Assets 471.2m - Total Current Liabilities 86.2m) / Total Assets 472.7m
B: -3.28 (Retained Earnings -1.55b / Total Assets 472.7m)
C: -0.29 (EBIT TTM -162.6m / Avg Total Assets 556.7m)
D: 0.10 (Book Value of Equity 41.6m / Total Liabilities 431.0m)
Altman-Z'' = -7.20 = D
Beneish M -1.12
DSRI: 0.57 (Receivables 60.7m/21.5m, Revenue 217.2m/43.7m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.00 (AQ_t 0.00 / AQ_t-1 0.14)
SGI: 4.97 (Revenue 217.2m / 43.7m)
TATA: 0.07 (NI -243.2m - CFO -278.2m) / TA 472.7m)
Beneish M = -1.12 (Cap -4..+1) = D
What is the price of SNDX shares?

As of July 08, 2026, the stock is trading at USD 23.24 with a total of 2,253,975 shares traded. Over the past week, the price has changed by +6.70%, over one month by +37.03%, over three months by -5.68% and over the past year by +166.21%.

Current recommended Stop Loss: 21.30 (which is 8.3% or 2 ATR below the current price).

Is SNDX a buy, sell or hold?

Syndax Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy SNDX.

  • StrongBuy: 9
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the SNDX price?
Analysts Target Price 39 67.8%
Syndax Pharmaceuticals (SNDX) - Fundamental Data Overview as of 04 July 2026
Market Cap USD = 1.93b (1.93b USD * 1.0 USD.USD)
P/S = 8.9029
P/B = 44.4626
Revenue TTM = 217.2m USD
EBIT TTM = -162.6m USD
EBITDA TTM = -162.5m USD
Long Term Debt = 344.0m USD (from longTermDebt, last quarter)
Short Term Debt = 488k USD (from shortTermDebt, last quarter)
Debt = 346.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.40m
Net Debt = -5.31m USD (calculated: Debt 346.8m - CCE 352.1m)
Enterprise Value = 1.93b USD (1.93b + Debt 346.8m - CCE 352.1m)
Interest Coverage Ratio = -2.01 (Ebit TTM -162.6m / Interest Expense TTM 80.7m)
EV/FCF = -9.92x (Enterprise Value 1.93b / FCF TTM -194.4m)
FCF Yield = -10.08% (FCF TTM -194.4m / Enterprise Value 1.93b)
FCF Margin = -89.50% (FCF TTM -194.4m / Revenue TTM 217.2m)
Net Margin = -112.0% (Net Income TTM -243.2m / Revenue TTM 217.2m)
 Gross Margin = unknown ((Revenue TTM 217.2m - Cost of Revenue TTM 4.44m) / Revenue TTM)
 Tobins Q-Ratio = 4.08 (Enterprise Value 1.93b / Total Assets 472.7m)
Interest Expense / Debt = 23.27% (Interest Expense 80.7m / Debt 346.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -128.4m (EBIT -162.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.86 (Total Current Assets 471.2m / Total Current Liabilities 97.0m)
Debt / Equity = 8.33 (Debt 346.8m / totalStockholderEquity, last quarter 41.6m)
 Debt / EBITDA = 0.03 (negative EBITDA) (Net Debt -5.31m / EBITDA -162.5m)
 Debt / FCF = 0.03 (negative FCF - burning cash) (Net Debt -5.31m / FCF TTM -194.4m)
 Total Stockholder Equity = 94.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.70% (Net Income -243.2m / Total Assets 472.7m)
RoE = -256.7% (Net Income TTM -243.2m / Total Stockholder Equity 94.8m)
RoCE = -37.05% (EBIT -162.6m / Capital Employed (Equity 94.8m + L.T.Debt 344.0m))
 RoIC = -34.14% (negative operating profit) (NOPAT -128.4m / Invested Capital 376.1m)
 WACC = 10.10% (E(1.93b)/V(2.28b) * Re(8.61%) + D(346.8m)/V(2.28b) * Rd(23.27%) * (1-Tc(0.21)))
Discount Rate = 8.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.01 | Cagr: 8.22%
 [DCF] Fair Price = unknown (Cash Flow -194.4m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.30 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.17 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.47 | Chg30d=-1.63% | Revisions=+18% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.40 | Chg30d=-3.94% | Revisions=-30% | Analysts=12
EPS current Year (2026-12-31): EPS=-1.70 | Chg30d=-0.69% | Revisions=-31% | GrowthEPS=+48.4% | GrowthRev=+99.9%
EPS next Year (2027-12-31): EPS=-0.52 | Chg30d=-11.16% | Revisions=-18% | GrowthEPS=+69.2% | GrowthRev=+45.9%
[Analyst] Revisions Ratio: -19% (up=13, down=20)